GeneHealth - Your precision medicine

Neurodegeneration With Brain Iron Accumulation 6

Disease Details

Family Health Simplified

Buy Membership

Description: Neurodegeneration with brain iron accumulation 6 (NBIA6) is a rare genetic disorder characterized by progressive movement problems, spasticity, and cognitive decline due to abnormal iron deposition in the brain.
Type: Neurodegeneration with brain iron accumulation 6 (NBIA6) is a neurodegenerative disorder. It is transmitted in an autosomal recessive manner.
Signs And Symptoms: Neurodegeneration with brain iron accumulation 6 (NBIA6) is a rare genetic disorder characterized by the following signs and symptoms:

1. Movement disorders: These include dystonia (abnormal muscle tone leading to twisted postures), parkinsonism (slowness of movement, tremors), and chorea (involuntary, rapid movements).
2. Cognitive decline: Progressive intellectual deterioration, including memory loss and difficulties with problem-solving.
3. Psychiatric symptoms: Depression, anxiety, and changes in behavior or mood.
4. Eye symptoms: Optic atrophy (damage to the optic nerve), leading to vision problems.
5. Speech and swallowing difficulties: Dysarthria (slurred speech) and dysphagia (difficulty swallowing).

In the context of "nan," there is insufficient data or context to relate it specifically to NBIA6 as a sign, symptom, or aspect of the disease.
Prognosis: Neurodegeneration with brain iron accumulation 6 (NBIA6) is a rare genetic disorder. The prognosis varies depending on individual progression but generally involves progressive neurological decline. Symptoms may include movement disorders, cognitive impairment, and spasticity. The disease typically worsens over time, leading to increasing disability. Lifespan can be reduced, but specific outcomes vary widely among patients. There are currently no curative treatments, and management focuses on symptomatic relief and supportive care.
Onset: The onset of Neurodegeneration with Brain Iron Accumulation 6 (NBIA6) typically occurs in childhood or early adolescence. Symptoms can begin between ages 1 and 15, but most commonly around age 6.
Prevalence: The prevalence of Neurodegeneration with Brain Iron Accumulation 6 (NBIA6) is very rare, with only a few cases reported in the medical literature.
Epidemiology: Neurodegeneration with brain iron accumulation 6 (NBIA6) is an extremely rare genetic disorder. Epidemiological data for NBIA6 is limited because of its rarity and the fact that it is part of a broader category of disorders (NBIA) that involves abnormal iron accumulation in the brain. There are no precise prevalence or incidence rates for NBIA6 specifically, but NBIA disorders as a whole are estimated to have an incidence of about 1 to 3 per million people. Because of its rarity, detailed epidemiological studies are sparse, and cases are usually documented through case reports and small cohort studies.
Intractability: Neurodegeneration with brain iron accumulation 6 (NBIA6) is considered intractable. This means that there is currently no cure or highly effective treatment to halt or reverse the disease progression. Management primarily focuses on symptom relief and supportive care.
Disease Severity: Neurodegeneration with brain iron accumulation 6 (NBIA6) typically presents with variable disease severity. Symptoms can range from mild to severe and often worsen over time. Clinical manifestations may include motor dysfunction, spasticity, dystonia, and cognitive decline. The rate of disease progression and the severity of symptoms can differ significantly among individuals.
Healthcare Professionals: Disease Ontology ID - DOID:0110740
Pathophysiology: Neurodegeneration with brain iron accumulation (NBIA) type 6 is a rare genetic disorder characterized by the abnormal accumulation of iron in the brain, particularly in the basal ganglia. This condition is caused by mutations in the C19orf12 gene, which is believed to play a role in lipid metabolism and mitochondrial function. The exact pathophysiological mechanisms are not yet fully understood, but the iron deposition is thought to contribute to oxidative stress and neuronal damage, leading to progressive motor and cognitive dysfunction.
Carrier Status: Neurodegeneration with brain iron accumulation 6 (NBIA6) is associated with mutations in the C19orf12 gene. Carrier status means that an individual carries one copy of a mutated gene but typically does not show symptoms of the disease. Carriers can, however, pass the mutated gene to their offspring, who may develop the disease if they inherit two defective copies, one from each parent.
Mechanism: Neurodegeneration with brain iron accumulation 6 (NBIA6), also known as COASY Protein-Associated Neurodegeneration (CoPAN), is a rare genetic disorder characterized by abnormal accumulation of iron in the brain, particularly in the basal ganglia, leading to progressive neurological deterioration.

**Mechanism:**
- NBIA6 is caused by mutations in the COASY gene, which encodes the CoA synthase enzyme. This enzyme is essential for the final steps of the coenzyme A (CoA) biosynthesis pathway.
- CoA is critical for multiple cellular functions including the synthesis and oxidation of fatty acids, and the metabolism of amino acids, carbohydrates, and steroids.

**Molecular Mechanisms:**
- Mutations in COASY disrupt the production of functional CoA synthase, thereby impairing CoA biosynthesis.
- This deficit reduces the availability of CoA, which can impair numerous biochemical pathways and cellular processes.
- The exact mechanistic link between CoA deficiency and iron accumulation in the brain is not fully understood, but it is believed that disruptions in metabolic homeostasis and mitochondrial dysfunction play significant roles.
- These mitochondrial dysfunctions could facilitate neuronal death and lead to the progressive neurodegenerative symptoms observed in NBIA6.
Treatment: For neurodegeneration with brain iron accumulation 6 (NBIA6), there is no definitive cure. Treatment primarily focuses on managing symptoms and may include:

1. **Iron Chelation Therapy**: To reduce iron accumulation in the brain.
2. **Medication**: Drugs to manage symptoms like dystonia, spasticity, and parkinsonism.
3. **Physiotherapy**: To improve mobility and maintain muscle strength.
4. **Speech and Occupational Therapy**: To help with communication and daily living skills.
5. **Surgical Interventions**: In some cases, deep brain stimulation (DBS) may be considered.

Research is ongoing to better understand NBIA6 and develop targeted therapies.
Compassionate Use Treatment: Neurodegeneration with Brain Iron Accumulation 6 (NBIA6) is a rare genetic disorder characterized by the abnormal accumulation of iron in the brain, leading to progressive motor and cognitive decline. For NBIA6, there are no widely approved treatments, but some off-label or experimental treatments may be considered:

1. **Iron Chelators**: Agents like Deferiprone and Deferasirox are used off-label to reduce brain iron levels. Their efficacy in NBIA6 specifically is still being studied.

2. **Antioxidants**: Compounds such as Coenzyme Q10, Vitamin E, and Deferiprone have shown potential in reducing oxidative stress, which may help alleviate symptoms.

3. **Deep Brain Stimulation (DBS)**: Experimental use of DBS targeting specific brain regions has been explored to manage dystonia and other motor symptoms.

4. **Gene Therapy**: Emerging research focuses on gene therapy to correct the underlying genetic mutations responsible for NBIA6.

5. **Symptomatic Treatments**: Medications like Baclofen, Tizanidine, and Botulinum toxin are used off-label to manage muscle spasticity and dystonia.

Compassionate use programs might allow access to these experimental therapies for severe cases where no other treatment options are available. Clinical trials and ongoing research are essential to better understand and develop effective treatments for NBIA6.
Lifestyle Recommendations: For neurodegeneration with brain iron accumulation 6 (NBIA6), lifestyle recommendations generally focus on supportive care to manage symptoms and improve quality of life. These may include:

1. **Regular Medical Care:** Consistent follow-ups with a neurologist and other specialists to monitor and manage symptoms.
2. **Physical Therapy:** Engaging in physical therapy to maintain mobility and muscle function.
3. **Occupational Therapy:** Occupational therapy can help individuals adapt to daily activities and maintain as much independence as possible.
4. **Speech Therapy:** To address any difficulties with speech or swallowing.
5. **Healthy Diet:** Maintaining a balanced diet to promote overall health. Consultation with a nutritionist may be helpful.
6. **Exercise:** Regular, moderate exercise can help maintain muscle strength and coordination.
7. **Emotional and Psychological Support:** Counseling or support groups to provide emotional and psychological support for patients and caregivers.
8. **Safety Measures:** Implementing home safety modifications to prevent falls and injuries.

These recommendations should be personalized based on the individual's specific symptoms and the progression of the disease.
Medication: Neurodegeneration with Brain Iron Accumulation Type 6 (NBIA6) currently has no definitive cure. Treatment typically focuses on symptom management and may include medications such as:

1. **Iron Chelators:** Deferiprone may be used to reduce brain iron levels.
2. **Muscle Relaxants:** Baclofen or tizanidine may help manage spasticity.
3. **Antiparkinsonian Drugs:** Levodopa or other medications can alleviate parkinsonian symptoms.
4. **Anticonvulsants:** To control seizures if they occur.

Additionally, supportive treatments such as physical therapy, occupational therapy, and speech therapy are often recommended to improve quality of life. Always consult a healthcare professional for personalized medical advice.
Repurposable Drugs: Neurodegeneration with brain iron accumulation 6 (NBIA6) is a genetic disorder characterized by iron buildup in the brain, leading to progressive neurodegeneration. Repurposable drugs for this condition are being researched but are not yet well-established. Some treatments that have been considered for potential repurposing include:

1. **Deferiprone**: An iron chelator that helps remove excess iron from the body and has been considered in some cases of NBIA disorders.
2. **Deferasirox**: Another iron chelator that might be explored for managing iron accumulation in the brain.

Since NBIA6 is a rare condition, clinical trials and more research are needed to confirm the efficacy and safety of these drugs in this specific context. It's essential to consult a healthcare professional for tailored medical advice.
Metabolites: Neurodegeneration with brain iron accumulation 6 (NBIA6) is associated with specific metabolic alterations, but specific metabolites impacted by NBIA6 have not been extensively characterized. However, abnormalities in pathways involving iron metabolism, mitochondrial function, and potentially lipid metabolism may be involved due to pantothenate kinase 2 (PANK2) gene mutations, which cause this condition. Detailed metabolomic studies are needed to identify precise metabolite changes.

If "nan" refers to a unique identifier or specific context, additional information is required for accurate interpretation.
Nutraceuticals: Neurodegeneration with Brain Iron Accumulation 6 (NBIA6) is a rare, genetic disorder characterized by abnormal iron deposits in the brain, leading to progressive motor and cognitive decline. Nutraceuticals may be considered as part of supportive care, although no specific nutraceuticals have been definitively proven to alter the disease course. Antioxidants like vitamin E, coenzyme Q10, and certain polyphenols might theoretically offer some neuroprotective effects, but clinical evidence is limited.

There have also been experimental approaches using nanotechnology, such as nanoparticles designed to deliver drugs across the blood-brain barrier or to chelate excess iron directly within the brain. However, these nanotechnology-based treatments are still in the research phase and are not yet available for clinical use.
Peptides: Neurodegeneration with brain iron accumulation 6 (NBIA6), also known as Kufor-Rakeb syndrome, is a rare genetic disorder characterized by the accumulation of iron in the brain, leading to progressive neurodegeneration. The involvement of peptides in this condition is not well-defined, but several studies focus on protein aggregation and malfunction.

However, nanotechnology (nan) offers promising therapeutic approaches for neurodegenerative diseases, including NBIA6. Nanoparticles can potentially be used for targeted drug delivery, crossing the blood-brain barrier, and reducing iron accumulation. This approach is still largely experimental but represents a burgeoning area of research with the potential for future treatments.